The global Immunoassay market is projected to grow from USD 35.5 billion in 2025 to USD 47.7 billion by 2030, at a CAGR of 6.1% during the forecast period. Market growth is primarily driven by the expanding elderly population and the increasing prevalence of chronic and age-related diseases such as cancer, diabetes, and cardiovascular conditions.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436
As healthcare systems worldwide emphasize early and accurate diagnosis, immunoassays continue to play a critical role in disease detection, monitoring, and management. Additionally, emerging markets are creating new growth opportunities, supported by increasing investments in research and development and improving healthcare infrastructure.
Reagents & Kits Segment Leads Product Market
By product, the reagents & kits segment accounted for the largest share of the immunoassay market in 2024. This dominance is largely attributed to their recurring usage in diagnostic workflows.
Unlike analyzers, which represent a one-time capital investment, reagents and kits are consumed with every test, making them essential for routine laboratory operations. Their continuous demand across a wide range of applications—including infectious diseases, endocrinology, and oncology—ensures steady revenue generation and market leadership.
ELISA Technology Maintains Market Dominance
By technology, ELISA (enzyme-linked immunosorbent assay) held the largest share of the immunoassay market in 2024. Its widespread adoption is driven by its high sensitivity, specificity, cost-effectiveness, and versatility across multiple diagnostic applications.
ELISA is particularly prominent in infectious disease testing and cancer screening, where reliable and accurate results are essential. Ongoing advancements in assay design and integration with automated systems are further enhancing its efficiency and reinforcing its position as a leading immunoassay technology.
Hospitals & Clinics Segment Leads End User Market
By end user, hospitals and clinics accounted for the largest share of the immunoassay market in 2024. These healthcare settings are central to diagnostic testing, particularly for acute and chronic conditions that require rapid and precise results.
Hospitals are equipped with advanced immunoassay platforms capable of handling high testing volumes and complex diagnostic panels. The growing adoption of automated and multiplex immunoassay systems is improving turnaround times and diagnostic accuracy, further driving demand within this segment.
Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=436
North America Dominates Global Market
North America held the largest share of the immunoassay market in 2024, supported by advanced healthcare infrastructure and the strong presence of leading diagnostic companies.
The United States plays a key role in regional dominance, driven by high demand for advanced diagnostic technologies and increasing disease burden. Strategic collaborations between regulatory bodies and research organizations—such as the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration (FDA)—have contributed to the development of standardized guidelines and improved assay validation processes.
These initiatives have strengthened confidence in immunoassay performance, accelerated technology adoption, and positioned North America as a hub for innovation and regulatory leadership in the global market.
Competitive Landscape
Key players in the global immunoassay market include Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher (US), Revvity (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A. (Italy), and Bio-Rad Laboratories, Inc. (US), among others.
These companies are focusing on technological advancements, automation, and strategic collaborations to strengthen their market positions and meet the growing demand for high-performance diagnostic solutions.
